These findings confirm that the combined use of SGLT2 inhibitors and finerenone can further impede the progression of kidney disease in patients with CKD, emphasizing the need for validation through a large-scale prospective clinical trial. This evidence concerns the gene SLC5A2 and chronic kidney disease.